Landmark Bio has entered into a pivotal strategic manufacturing agreement with Galapagos NV, signaling a notable advance in the field of genomic medicines. This multi-year agreement positions Landmark Bio to produce clinical trial batches for Galapagos’ CAR T-cell therapies, with an emphasis on hematology-oncology, within the biotech hub of the Boston metropolitan area.

Accelerating CAR-T Therapy Delivery

Through this alliance, the focus is on implementing Galapagos’ pioneering decentralized CAR-T manufacturing model. The goal is a significant reduction in the delivery time of CAR T-cells following leukapheresis to an average of seven days, potentially addressing the shortcomings of current CAR-T treatment methodologies.

Landmark Bio’s Pioneering Facility

Ran Zheng, CEO of Landmark Bio, highlighted the partnership as a validation of Landmark Bio’s specialized capabilities in cell and gene therapy manufacturing. The alliance is aligned with the company’s mission to accelerate the availability of life-saving treatments to patients. Landmark Bio’s facility encompasses a 44,000 square-foot area equipped for a full spectrum of research and development services, featuring a biomanufacturing space with nine cleanrooms designated for various advanced therapeutic production processes, complemented by in-house quality control.

The specifics of the financial agreement between Landmark Bio and Galapagos NV have not been disclosed, but the collaboration is undoubtedly a leap forward in the manufacturing and accessibility of cutting-edge CAR-T therapies.

  Boston, Galapagos, Landmark Bio, Oncology, Ran Zheng, USA